Clinical Trial Update: Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of abemaciclib plus nivolumab in hepatocellular carcinoma was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)
• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-12-14